Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares saw strong trading volume on Friday . 308,340 shares changed hands during trading, an increase of 154% from the previous session’s volume of 121,183 shares.The stock last traded at $10.58 and had previously closed at $10.65.

Several research analysts have recently weighed in on the company. Needham & Company LLC restated a “buy” rating and set a $30.00 target price (up from $28.00) on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. Zacks Investment Research upgraded Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, May 24th. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $26.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, May 26th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $28.25.

The company’s 50-day moving average price is $12.18 and its 200-day moving average price is $16.08. The firm’s market cap is $248.69 million.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by $0.29. On average, equities analysts anticipate that Collegium Pharmaceutical Inc. will post ($3.88) EPS for the current fiscal year.

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.